News & Analysis as of

Life Sciences Startups Investment

Mintz - Venture Capital & Emerging Companies...

Mintz Venture Watch — Volume 8: A Report on Deal Trends from 2024 and H1 2025

Despite continued macroeconomic headwinds and a cautious investment climate, Mintz’s Venture Capital and Emerging Companies practice remained highly active throughout 2024 and into the first half of 2025. Our team advised on...more

Orrick, Herrington & Sutcliffe LLP

From Federal to State: Building the New Life Sciences Capital Stack | Life Sciences Snapshot – Q3 2025

This year, U.S. VC funding into the life sciences sector has cooled: Q1 softness was followed by a decade low in VC transactions in Q2. Despite the moderation in dealmaking volume, investors continued to deploy sizable...more

Goodwin

Fundraising Strategies for Early-Stage Medtech Startups

Goodwin on

Investor interest in the medtech sector is strong. According to DealForma and JPMorgan, medtech companies raised $16.1 billion from 544 funding rounds, including $3.3 billion from 244 seed and Series A rounds, through the...more

Fenwick & West Life Sciences Group

Rock Health Summit Takeaway: Digital Health is Rightsizing, Not Retreating

From its inception, digital health has been focused on developing technologies and solutions that offer a higher quality of healthcare to more people at a lower cost. Amidst fluctuations in stock prices, valuations and...more

UB Greensfelder LLP

How Silicon Valley Bank's Shutdown Affects Venture Companies

UB Greensfelder LLP on

Among America’s largest banks and formerly well-regarded by analysts, investors, and venture-backed companies alike, the sudden failure of Silicon Valley Bank (SVB) last week sent shockwaves through the venture capital and...more

Orrick, Herrington & Sutcliffe LLP

Deal Flow 3.0: European Venture Capital Deal Term Review 2022

Foreword - Despite a shift to economic headwinds, investors injected more than $95B into the European tech market in 2022, the second-largest amount ever. To see how deal terms changed, Orrick developed new technologies and...more

Allen Matkins

Life Sciences Real Estate Update - December 2022

Allen Matkins on

The slowdown in funding for the life sciences sector over the second half of 2022 has been pronounced. Carta, a firm that tracks startup investments, found that biotech seed funding, which hit quarterly peaks of roughly $400...more

Fenwick & West LLP

Life Sciences Summit: Biotech IPO Market Shows Signs of Life

Fenwick & West LLP on

As biotech markets begin to show signs of life, how should company leaders and investors prepare for what’s next?  Biotech executives, investment bankers and partners from Deloitte’s life sciences practice and Fenwick’s...more

Fenwick & West Life Sciences Group

Market Slowdown is Opportunity for Digital Health Companies to Hone Focus, Deliver Bold Yet Tenable Plans

There are more investors in digital health today than there have ever been, but the questions they are posing to company founders before writing a check are tougher than they were just a year ago....more

Fenwick & West Life Sciences Group

Digital Health Has Strong Fundamentals to Pull Through Downturn

Digital health has been a powerhouse investment sector since it emerged more than a decade ago. Year-after-year, startups consistently demonstrate their innovations bring real-world benefits and our healthcare system...more

Fenwick & West Life Sciences Group

Economic Conditions Changing, but Digital Health Still Strong

The digital health sector emerged as a juggernaut during the COVID-19 pandemic, with almost $15 billion invested in privately-held digital health companies in 2020 and nearly $30 billion invested last year, according to our...more

Fenwick & West Life Sciences Group

The Most-Funded Year Ever for Digital Health Startups – New Trends, Opportunities Emerge in Q3

At the end of Q3, aggregate funding raised by digital health startups in 2021 surpassed $20 billion. Although 2021 continues to be a record-breaking year for digital health startups, investors gently tapped the breaks in Q3....more

Fenwick & West Life Sciences Group

Digital Health Investors Offer Cautious Optimism at Rock Health H1 2020 Event

Venture investors are pleased to see digital health companies continue to transform the healthcare system despite unprecedented challenges brought by the COVID-19 pandemic....more

Mayer Brown Free Writings + Perspectives

Global Healthcare Financing Trends During COVID-19

During the first quarter of 2020, venture funding levels in the global healthcare and life sciences sector has increased 4% by dollars raised, quarter-over-quarter, despite the turbulent COVID-19 environment. According to a...more

Fenwick & West Life Sciences Group

Key Takeaways from Fenwick’s 2019 Digital Health Investor Summit

Fenwick’s eighth annual Digital Health Investor Summit took place against the backdrop of strong and increasingly diverse investment markets, a focus on clinical validation of digital health tools, and a healthcare system...more

Fenwick & West Life Sciences Group

Five Takeaways From Fenwick’s Sixth Annual Digital Health Investor Summit

Fenwick’s Sixth Annual Digital Health Investor Summit started on an upbeat note with Rock Health’s Megan Zweig sharing the venture fund’s mid-year funding report. After the uncertainty brought by the 2016 presidential...more

Fenwick & West Life Sciences Group

Payer/Provider Digital Health Investments Increase in Q1 2017

Last September, we noted that payers and providers were expected to become increasingly active digital health strategic investors given their challenges to improve margins and outcomes....more

17 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide